FMP
HAEMATO AG
HAEK.DE
XETRA
Inactive Equity
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European imported drugs and medical products; and manufactures and distributes its generic drugs. It provides pharmaceuticals in the areas of oncology, HIV, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic medicine, as well as cosmetic products. The company also develops and markets medical devices and medical technology products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors, clinics, and medical laboratories. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany.
21.4 EUR
-0.4 (-1.87%)
DuPont Analysis
The DuPont analysis, pioneered by the DuPont Corporation, offers a structured approach to assessing fundamental performance. It involves breaking down the return on equity (ROE) into various components, aiding investors in comprehending the factors influencing a company's returns.
ROE = Net Income / Average Total Equity
ROE = (Net Income / Sales) * (Revenue / Average Total Assets) * (Average Total Assets / Average Total Equity)
The company's tax burden is (Net income ÷ Pretax profit). This is the proportion of the company's profits retained after paying income taxes. [NI/EBT] The company's interest burden is (Pretax income ÷ EBIT). This will be 1.00 for a firm with no debt or financial leverage. [EBT/EBIT] The company's operating income margin or return on sales (ROS) is (EBIT ÷ Revenue). This is the operating income per dollar of sales. [EBIT/Revenue] The company's asset turnover (ATO) is (Revenue ÷ Average Total Assets). The company's equity multiplier is (Average Total Assets ÷ Average Total Equity). This is a measure of financial leverage. Profitability (measured by profit margin) Asset efficiency (measured by asset turnover) Financial leverage (measured by equity multiplier)
